Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
  • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
  • A61K9/2846—Poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• This present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophosphamide, processes for the preparation thereof, and their use to treat cancer diseases.
• capecitabine is the most commonly-used agent.
• Capecitabine has been approved by the Food and Drug Administration in the treatment of Metastatic breast cancer (METASTATIC BREAST CANCER) patients resistant to anthracyclines and/or taxanes.
• Capecitabine is widely used in different combination regimens due to better therapeutic and safety profile with lower side effects.
• the combination partner of capecitabine plays an important role for the activation of thymidine phosphorylase (TP) enzyme, which converts the capecitabine to active 5-FU.
• TP thymidine phosphorylase
• Cyclophosphamide is an anti-cancer chemotherapy drug. This medication is classified as an alkylating agent. Cyclophosphamide is a prodrug, converted in the liver to active forms that slow down the growth of cancer cells. Cyclophosphamide requires enzymatic and chemical activation to produce active form. Cyclophosphamide is used alone or in combination with other drugs to treat various cancers like METASTATIC BREAST CANCER, ovarian cancer, leukemia. When given orally, cyclophosphamide shows superior efficacy than when it is given intravenously.
• capecitabine and cyclophosphamide in present invention potentially provides an attractive, all oral alternative, giving patients more freedom and a sense of control over their treatment.
• cyclophosphamide and capecitabine may have a greater potential for treatment of METASTATIC BREAST CANCER due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by capecitabine.
• a marked reduction in the tumor volume was seen during the time period coincident with the dThdPase up-regulation.
• several clinical studies show that the efficacy of cyclophosphamide in combination with capecitabine was more than just additive to synergistic effects.
• WO 2013/028186 generally discloses a method of treating cancer comprising administering to the patient a single oral composition comprising a combination of at least two chemotherapeutic agents such as capecitabine and cyclophosphamide, optionally comprising additional therapeutic or chemotherapeutic agents, e.g., anti-emetics or cytotoxic compounds.
• chemotherapeutic agents such as capecitabine and cyclophosphamide
• additional therapeutic or chemotherapeutic agents e.g., anti-emetics or cytotoxic compounds.
• Inventors of the present invention investigated the development of a pharmaceutical composition comprising capecitabine and cyclophosphamide for oral administration.
• the present invention provides the advantages of combination therapy while reducing the number of prescriptions, number of tablets to be taken which results in better patient compliance and attendant administrative costs.
• Combination therapies with agents having complementary mechanisms of action may provide advantages of each type of agent and reduce some of the adverse effects of high-dose of individual drugs.
• the object of the present invention is to provide a solid pharmaceutical composition for oral administration comprising a fixed dose combination of capecitabine and cyclophosphamide in the form of a bilayer tablet, wherein the bilayer tablet comprises a first layer and a second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients, and further optionally comprising a film coating that covers both layers.
• Another object of the present invention is to provide a process for the preparation of the above pharmaceutical composition comprising a first layer and a second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients, and further optionally comprising a film coating that covers both layers.
• Another object of the invention is to provide the above pharmaceutical composition for use in treating metastatic breast cancer.
• the present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophosphamide in solid dosage form for oral administration, processes for the preparation thereof, and their use to treat cancer diseases. Further the combination of capecitabine and cyclophosphamide is an effective, convenient and well-tolerated regimen for Metastatic Breast Cancer.
• the present invention relates to a fixed dose combination comprising capecitabine and cyclophosphamide in the form of a bilayer tablet.
• Oral combination of capecitabine and cyclophosphamide are conventional drugs for the treatment and are an effective and well-tolerated regimen for Metastatic Breast Cancer.
• the pharmaceutical composition comprising a fixed dose combination present in solid dosage form, particularly in oral form, is a bilayer tablet.
• the fixed dose combination according to present invention is provided in the form of a pharmaceutical bilayer tablet composition
• a pharmaceutical bilayer tablet composition comprising a first layer and a second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients.
• the bilayer tablet further optionally comprises a film coating that covers both layers.
• excipients which may be used may typically be selected from the group consisting of one or more diluents or fillers, one or more binders, one or more glidants, one or more disintegrants, one or more lubricants, and the like.
• the amount of each excipient in a solid dosage formulation may vary within ranges conventional in the art.
• composition described herein may be prepared by conventional technology well known to those skilled in the art such as wet granulation, dry granulation and direct compression and the like.
• the first layer comprising capecitabine can be prepared by wet granulation as hereinafter described whilst the second layer comprising cyclophosphamide can be prepared by blending the excipients for direct compression.
• the second layer comprising cyclophosphamide can be prepared by wet granulation. Both layers can then be combined and compressed together as herein after described.
• the bilayer tablet dosage form may comprise a film coating. Suitable film coating is known and commercially available or can be made according to known methods.
• the film coating material is a polymeric film coating material comprising hydroxypropylmethyl cellulose, polyethylene glycol, polysorbate, sodium carboxy methyl cellulose, Talc, Titanium dioxide, simethicon, Eudragit, purified water and colorant.
• a bilayer tablet according to present invention generally contains 50-1800 mg, preferably 100-1500 mg, more preferably 300-800 mg capecitabine; and 10-100 mg, preferably 20-80 mg, more preferably 20-60mg cyclophosphamide.
• Presently preferred forms are bilayer tablet comprising 300/20 mg, 400/20 mg, 600/40 and 700/30 mg of capecitabine and cyclophosphamide, respectively.
• the first tablet layer according to present invention comprises capecitabine as active agent and one or more excipients.
• the capecitabine containing first layer of the invention is prepared by wet granulation.
• Alternative methods for granulation of the active ingredient and excipients with a granulation liquid are fluid bed granulation or top spray granulation.
• the granulating liquid is a solvent such as purified water, ethanol, isopropanol, acetone or mixture thereof, preferably purified water.
• the solvent is a volatile component, which does not remain in the final product.
• Excipients of the first layer may be particularly selected from the group consisting of one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
• the first layer of the bilayer tablet is prepared by wet granulation comprising following steps:
• a binder can be added with the blend obtained in step (a) and further granulation is done with a suitable solvent which would act as a granulation liquid.
• filler for first layer examples include, without being limited to, microcrystalline cellulose, mannitol, sucrose or other sugar or sugar derivatives, low substituted HPC, dicalcium phosphate, lactose and combination thereof.
• binder for first layer examples include, without being limited to, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, pregelatinized starch, maize starch, microcrystalline cellulose (e.g., cellulose MK GR), and combinations thereof.
• disintegrant for first layer examples include, without being limited to, croscarmelose sodium, crospovidone, sodium starch glycolate, starch, pregelatinized starch and combination thereof.
• lubricant for first layer examples include, without being limited to, magnesium stearate, calcium stearate, aluminum or calcium silicate, stearic acid, talc and combinations thereof.
• the second tablet layer according to present invention comprises cyclophosphamide as active agent and one or more excipients.
• the second layer comprises cyclophosphamide having a D90 particle size of less than 300 microns, more preferably 100 microns.
• the second layer of the bilayer tablet is prepared by direct compression comprising following steps:
• the second layer of the bilayer tablet can also be prepared by wet granulation comprising following steps:
• Excipients of the second layer may be particularly selected from the group consisting of one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
• filler for second layer examples include, without being limited to, dibasic calcium phosphate anhydrous, microcrystalline cellulose, lactose, mannitol, sucrose or other sugar or sugar derivatives, low substituted HPC, pregelatinized starch, and combination thereof.
• binder for second layer examples include, without being limited to, polyvinylpyrrolidone, povidone, copovidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, pregelatinized starch, maize starch, microcrystalline cellulose (e.g., cellulose MK GR), and combinations thereof.
• disintegrant for second layer examples include, without being limited to, croscarmelose sodium, crospovidone, sodium starch glycolate, starch, pregelatinized starch and combination thereof.
• lubricant for second layer examples include, without being limited to, magnesium stearate, calcium stearate, aluminum or calcium silicate, stearic acid, talc and combinations thereof.
• the first and second tablet layers prepared as described hereinabove may be compressed in the usual manner in a bilayer tablet press.
• Another preferred aspect of the present invention also includes an optional film coating on the bilayer tablet.
• the details regarding the film coating material component are as described herein above.
• capecitabine and cyclophosphamide are physically incompatible substances.
• both drugs were kept on 40°C (open) for 1 month, different type of impurities related with cyclophosphamide are obtained during preformulation studies.
• the % impurities related with cyclophosphamide obtained during the preformulation studies are as below.
• *Impurity B of cyclophosphamide is 3-aminopropyl dihydrogen phosphate.
• *Impurity C of cyclophosphamide is 3-3 chloroethyl-2-oxo-2-hydroxy-1, 3, 6, 2 oxadiazaphosphonane.
• *Impurity D of cyclophosphamide is Bis (2-chloroethyl)amine hydrochloride.
• Acceptable limits of the above said impurities of cyclophosphamide according to the present invention are individually not more than 0.5% w/w and the total impurity of cyclophosphamide should not be more than 3% w/w, when determined after one month when kept at 40°C.
• the pre-formulation studies for combination of capecitabine and cyclophosphamide do not comply with the above said acceptable limits.
• the present invention provides a pharmaceutical composition comprising a fixed dose combination of capecitabine and cyclophosphamide which has a greater potential for treatment of metastatic breast cancer.
• the present invention provides a better therapeutic efficacy by combined administration of capecitabine and cyclophosphamide rather than when used separately.
• Example 1 Mg/tab Example 2 Mg / Tab Capecitabine 300.0 600.0 Microcrystalline Cellulose (Avicel PH 112) 57.0 114.0 Croscarmellose Sodium 16.0 32.0 HPMC E-5 15.0 30.0 Purified Water q.s. q.s.
• Example 3 (mg / tab)
• Example 4 (mg / tab)
• Capecitabine 400.0 700.0
• Microcrystalline Cellulose (Avicel PH 101) 33.27 58.22 Lactose anhydrous 38.43 60.72
• Croscarmellose Sodium (Ac-di-sol) 13.25 23.19 HPMC E-5 18.55 32.46 Purified Water q.s. q.s.
• Cyclophosphamide 24.40 32.1 Pregelatinized starch (Starch 1500) 4.60 6.90 Croscarmellose Sodium (Ac-di-sol) 10.00 15.00 Talc 3.40 5.10 Colloidal anhydrous silica-E 1.70 2.55 Magnesium Stearate 3.40 5.10 Ferric oxide yellow 0.150 0.23 Total Layer II 170.0 255.0 Total Core Tablet weight 700.00 1185.00 Polyethylene glycol 4000 2.39 4.78 Polysorbate 80 0.49 0.98 Sodium carboxymethylcellulose 0.39 0.78 Talc 4.74 9.48 Titanium Dioxide 4.74 9.48 Eudragit NE30D 2.152 4.30 Ferric oxide yellow 0.09 0.18 Ferric oxide Red 0.004 0.01 Purified water q.s. q.s. Total coated tablet weight 715.00 1215.00
• Process for preparation of film coating is similar as example 1 and 2.
• bilayer tablets of fixed dose combination of capecitabine and cyclophosphamide prepared as per the compositions of example 1 to example 4 were subjected to dissolution studies in 900 ml of phosphate buffer pH 6.8 at 37 ⁇ 0.5°C using basket apparatus with rotational speed at 100 rpm.
• Table 2 provides dissolution profile of tablets prepared according to example 1 to example 4. Time (Min) % Drug Release Example 1 Example 2 Example 3 Example 4 5 7 6 10 09 10 24 15 38 23 15 45 26 52 40 20 69 40 81 63 30 94 73 99 91 45 100 93 103 101 60 100 97 103 103
• Impurity profile of the pharmaceutical compositions according to examples 1 to 4 meets the acceptance criteria of individual and total impurities of cyclophosphamide as disclosed hereinabove.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (3)

Family

ID=52744637

Family Applications (1)

Country Status (9)

Families Citing this family (3)

Family Cites Families (5)

• 2014
  • 2014-09-29 BR BR112016007031A patent/BR112016007031A8/pt not_active IP Right Cessation
  • 2014-09-29 MX MX2016004094A patent/MX2016004094A/es unknown
  • 2014-09-29 IN IN3118MU2013 patent/IN2013MU03118A/en unknown
  • 2014-09-29 US US15/025,819 patent/US20160243034A1/en not_active Abandoned
  • 2014-09-29 CA CA2925960A patent/CA2925960A1/en not_active Abandoned
  • 2014-09-29 WO PCT/IN2014/000625 patent/WO2015044961A2/en active Application Filing
  • 2014-09-29 EP EP14850037.4A patent/EP3052130B1/en active Active
  • 2014-09-29 AU AU2014326142A patent/AU2014326142B2/en not_active Ceased
  • 2014-09-29 ES ES14850037T patent/ES2753435T3/es active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events